Please assess the completion status of the following clinical trial:

Trial Title: CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria Pre-emptive arm~Children (18 years or younger) with CD19+ precursor B cell ALL fulfilling one of the following criteria who are undergoing an allogeneic stem cell transplant from an EBV-seropositive donor:~In first remission, if at least one of the following criteria are met:~* t(9;22) and MRD positive (BCR-ABL/ABL ratio \> 0.01%) after HR3 block of EsPhALL or pre-HSCT or~* Infant ALL age \< 6 months at diagnosis with MLL gene rearrangement and either presenting wcc \>300 x 10\^9/L or poor steroid early response (i.e circulating blast count \>1x10\^9/L following 7 day steroid pre-phase of Interfant 06) or~* Resistant disease (\> 30% blasts at end of induction treatment day 28-33) in subsequent morphological CR or~* High level bone marrow MRD (\> 1 in 1000) at week 12 ALL-BFM 2000/AIEOP BFM ALL 2009/EORTC 58951 protocols, week 12-15 of FRALLE A or at week 14 of UKALL2011~Relapsed patients if at least one of the following criteria are met:~* Very early (\< 18 months from diagnosis) bone marrow or extramedullary relapse in second CR or~* Early (within 6 months of finishing therapy) isolated bone marrow relapse with bone marrow MRD \> 1 in 100 at day 35 of reinduction in second CR or~* Early (within 6 months of finishing therapy) bone marrow or combined relapse with high level bone marrow MRD (\> 1 in 1000) at the end of consolidation therapy (week 12-13 UKALL R3/INTREALL and COOPRALL protocols, prior to protocol M in BFM relapse protocol (ALL-REZ BFM 2002) and after Protocol II-IDA in AIEOP LLA Rec 2003)or~* Any relapse of infant or Philadelphia-positive ALL in morphological complete remission~* Any patient being transplanted in 3rd or greater CR~These patients have a high (\> 50%) risk of relapse and will be monitored for evidence of MRD in bone marrow aspirates (monthly for months 1-6, 6 weekly months 7.5-12 post HSCT) for the first year post-transplant. Patients who become MRD +ve in the marrow at a level minimum 5 x 10-4 (or BCR-ABL/ABL ratio 0.05% in Ph+ve ALL patients with no IgH MRD marker) but are in morphological remission (\<5% blasts in BM) will be eligible to be treated pre-emptively with CD19ζ transduced CTL~Prophylaxis arm~Additionally, any patient (≤ 18 years) with ALL relapsing in the bone marrow (isolated or combined) after myeloablative allogeneic HSCT who achieves morphological remission after re-induction and who is a candidate for second HSCT at one of the participating centres is eligible to receive CD19ζ transduced CTL prophylactically~* Stem cell donors must be EBV sero-positive and HLA-matched (8/8 HLA A,B,C and DR at medium resolution typing) or a single antigenic/allelic (7/8) mismatch with the recipient~* A life expectancy of at least 12 weeks~* Karnofsky score of \>60% if \>10 years old or Lansky performance score of \>60 if ≤ 10 years old~* Patients must have transduced donor-derived EBV-specific CTLs with 15% or higher expression of CD19ζ determined by flow-cytometry which meet the specified release criteria~* Informed written consent indicating that patients are aware this is a research study and have been told of its possible benefits and toxic side effects~Exclusion Criteria~* Patients with CD19 negative precursor B cell ALL~* EBV seronegative or \> single antigenic/allelic HLA-mismatched donor~* Active acute GVHD overall Grade 2 or higher or significant chronic GVHD requiring systemic steroids at the time of scheduled infusion of transduced CTL will be excluded until the patient is GVHD-free and off steroids~* Pre-existing severe lung disease (FEV1 or FVC \< 50% predicted) pre-HSCT or an oxygen requirement of \>28% O2 supplementation or active pulmonary infiltrates on chest X-ray at the time scheduled for transduced CTL infusion~* Serum bilirubin \>3 times the upper limit of normal or an AST or ALT \> 5 times the upper limit of normal~* Serum creatinine \>3 times upper limit of normal~* Active severe intercurrent infection at the time of transduced CTL infusion (if present consult with Chief investigator).~* Patients in whom transduced donor-derived EBV-specific CTLs don't meet release criteria~* Serologically positive for Hepatitis B, C or HIV pre-HSCT~* Females of childbearing age with a positive pregnancy test~* Known allergy to DMSO

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Prophylaxis arm (Type: EXPERIMENTAL): Patients who have relapsed in the bone marrow after previous myeloablative HSCT and achieve remission after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells after a second HSCT with reduced intensity conditioning.
- Pre-emptive arm (Type: EXPERIMENTAL): In this arm, patients identified at high (\> 50%) risk of relapse will be eligible for generation of donor-derived EBV CTL immediately prior to HSCT. These patients will be monitored for evidence of MRD in regular bone marrow aspirates for the first year post-HSCT. MRD positivity post-HSCT is highly predictive of subsequent relapse. In those patients who become MRD+ in the marrow at a level of minimum 5 x 10-4, cryopreserved CTL that have been transduced with a retroviral vector carrying the CD19-zeta transgene will be thawed and administered to the patient pre-emptively.

Based on this trial design, predict the completion outcome and termination type (if applicable).